Randomized controlled study finds significant healing and anti-infective
benefits, providing hope for patients and caregivers
PRINCETON, N.J., Sept. 15 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI) announced today that its key product, MEDIHONEY(TM) Wound & Burn Dressing with Active Leptospermum Honey, has been found in a large randomized controlled clinical trial to significantly improve the healing rates of stalled venous leg ulcers. Prior to this study, no other advanced wound care dressing, under compression therapy, had been shown to improve healing rates of leg ulcers. Physicians treat over 4 million leg ulcers in the US per year, at a cost exceeding $1 billion.
The trial, a 108-patient randomized and controlled clinical trial, looked at venous leg ulcers that had been proven to be non-healing under standard treatment (compression therapy). In the study, half the patients had a common advanced wound care gel added to the standard treatment, and half had Comvita's Active Leptospermum (Manuka) Honey (now marketed under the brand name MEDIHONEY) added. After four weeks, the mean reduction in size of the wounds was 34% in the honey group and 13% in the control group. After 12 weeks, there was a 44% complete healing rate in the honey group vs. only 33% in the control group. Both these differences were statistically significant.
The findings were published in the Journal of Clinical Nursing, and were written by lead investigators Georgina T. Gethin and Seamus Cowman, both of the Royal College of Surgeons in Ireland. They concluded that, "the [honey] group had shown a greater incidence of healing, more effective desloughing, and lower incidence of infection than the control group."
CEO Ed Quilty stated, "We are pleased that this important finding has been recognized in such a well-regarded peer reviewed journal serving the global market. Since the product's launch in Europe a couple of years ago, and then the launch in the US and Canada this year, clinicians have consistently reported that MEDIHONEY is effective on stalled ulcers of various etiologies. The recently published study now provides clear evidence of this by demonstrating results proven in a rigorous randomized controlled study. Clinicians can now feel confident in the value that they place on MEDIHONEY and the role it has to play in an overall treatment strategy.
This is significant for our product as currently, only 50% of chronic wounds heal with first-line treatment options. It is also significant for patients who suffer the effects of notoriously painful leg ulcers, with uncommonly long durations - sometimes lasting years."
Wound care is a major healthcare market with an estimated value of $10 billion in 2007 that is expected to grow to $12.5 billion by 2012. The global growth is being driven by several factors, including an aging population, the rise in the global incidence of diabetes and chronic vascular disorders, and a steady advancement in wound care technologies.
The Journal of Clinical Nursing (JCN) is an international, peer reviewed, scientific journal that seeks to promote the development and exchange of knowledge that is directly relevant to all spheres of nursing practice. The primary aim is to promote a high standard of clinically related scholarship which supports the practice and discipline of nursing. JCN publishes high quality papers on issues related to clinical nursing, regardless of where care is provided. This includes - but is not limited to - ambulatory care, community care, family care, home, hospital, practice, primary and secondary, and public health.
For more information on the Journal of Clinical Nursing, please visit: http://www.blackwellpublishing.com/journal.asp?ref=0962-1067
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound-
care products. Its key product, MEDIHONEY, is sold throughout the world by
Derma Sciences and Comvita New Zealand -- the licensor of the patented
honey- based technology -- and is the leading brand of honey-based
dressings for the management of wounds and burns. The product has been
shown to be effective in a variety of wounds and burns, and was recently
the focus of a large-scale randomized controlled trial on leg ulcers. Derma
has two products in development: the BIOGUARD(TM) line of barrier gauze
dressings, and DSC127, the company's novel angiotensin analog for
accelerated wound healing and scar reduction. The barrier technology was
licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA
marketing clearance. DSC127 was licensed from The University of Southern
California in Q4 of 2007 and is entering into a Phase II study, with
anticipated initial patient enrollment to begin in Q3 of 2008. For more
information about Derma Sciences, Inc., visit its home page on the Internet
Contact: Derma Sciences, Inc. Allen & Caron Inc
Edward J. Quilty Rudy Barrio (US Investors)
Chairman and CEO email@example.com
(609) 514-4744 Brian Kennedy (media)
|SOURCE Derma Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved